Clinical Trial Update: A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women [Phase 1]

View source ↗

Summary

Phase 1 open-label study to evaluate the pharmacokinetics and safety of DARE-HRT1 in healthy postmenopausal women has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause
• Vulvar and Vaginal Atrophy

Drugs mentioned

• DARE-HRT1

Snippet

Sponsor: Daré Bioscience, Inc. | Conditions: Vulvovaginal Atrophy, Vasomotor Symptoms | Phase 1 | Status: COMPLETED | Results posted: 2024-10-15